FDA Finalizes Guidance on Pharmaceutical Lifecycle Management

News
Article

The guidance provides a framework for the management of postapproval chemistry, manufacturing, and controls changes.

FDA announced on May 11, 2021 that it has made the final version of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) Q12 Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management available. The guidance provides a framework for managing postapproval chemistry, manufacturing, and controls (CMC) changes and discusses necessary elements for assuring product quality in a regulatory submission changed postapproval. The guidance also promotes manufacturing innovations through a risk-based approach to regulatory oversight and continued product improvement, which may mitigate manufacturing and quality issues. The guidance document’s Annexes provide examples of how tools described in ICH Q12 could be applied.

Source: FDA

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes